Keynote – AI and Genomics Powered Modern Pathology is the Engine of Precision Medicine
Marilyn M. Bui, MD, PhD, Scientific Director, Analytic Microscopy Core; Section Head, Bone & Soft Tissue Pathology, Moffitt Cancer Center (Tampa, FL) ; Professor & Program Director, Cytopathology, University of South Florida Morsani College of Medicine
Digital pathology (DP) and AI are the 3rd revolution in pathology marked by the milestones including the 1st digital scanner cleared by the FDA for primary diagnosis in 2017, the AI pathology solutions released in 2018, and the remote sign-out in routine practice using whole slide images during COVID19 pandemic. Biomarker testing, largely done by pathology and laboratory medicine, provides diagnostic, prognostic and predictive information to direct the delivery of precision medicine (PM). With the combined power of genomics and AI, pathology and laboratory medicine will transform and optimize the quality, efficiency and value of PM. This talk will illustrate the potential of DP/AI in PM, discuss the challenges in DP/AI development and implementation, highlight examples of good practice and resources, emphasize the importance of embracing DP/AI by pathologists, and call for collaboration of the medical and scientific community in the digital health revolution to ultimately benefit patient care.
Digital Pathology and Image Analysis: is Now the Time?
Alexander Haragan, PhD, MBBS, Pathology, NHS; Clinical Research Fellow, Pathology, Liverpool Clinical Laboratories, LLC
As digital pathology emerges as a vital technology in the laboratory, novel techniques such as image analysis are transforming the pathology workflow. Dr. Haragan will discuss how digital pathology solutions are changing the workflow for pathology, how these developments align with immunohistochemistry and molecular pathology advancements, and how his work with PD-L1 image analysis tools demonstrated advantages in the routine clinical workspace.
Thomas J. Fuchs, DrSc, Founder and Chief Scientist, Paige
Digital Pathology Solutions for Drug Development and Diagnostics
Moderator: Steve Anderson, PhD, Chief Scientific Officer, Senior Vice President, LabCorp Drug Development
Panelists: Carlee Hemphill, MSc, Lead Scientist, LabCorp Drug Development; Mike Montalto, PhD, Chief Scientific Officer, PathAI
There has been a growing body of supporting evidence in the translational research field showing the role genomic- and proteomic-based platforms in enabling more informed and potentially effective therapeutic strategies in clinical development and when appropriate transitioning to diagnostic applications. Topics of discussion include:
The landscape of innovative tools and technology within multi-omics that can provide comprehensive clinical trial testing solution.
Combination of digital pathology for IHC, gene expression profiling, digital spatial profiling for a deeper investigation of disease biology.
Implementation of AI-powered digital pathology into clinical trials to better identify target populations therapy selection and to support downstream diagnostic development.